Today, insitro announces an exciting new collaboration with the INSIGHT Eye Hub at Moorfields Eye Hospital, London to develop a novel #AI imaging foundation model. The work will leverage the world's largest ophthalmic imaging bioresource with 35 million eye images, including Optical Coherence Tomography (OCT) data linked to several decades of clinical information. “OCT data at this scale contains a treasure trove of information about human health, providing a new window into diseases of the brain, the eye, and more,” said Daphne Koller, CEO and founder of insitro. This work will unlock ocular biomarkers for precision patient segmentation and drive the discovery of novel therapeutic targets and support insitro’s #neuroscience programs. To learn more, you can read the full press release here: https://lnkd.in/et2Rhmei
insitro
生物技术研究
South San Francisco，California 29,261 位关注者
Making medicines differently to bring better drugs faster to the patients who benefit most with ML and data at scale.
关于我们
insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.
- 网站
-
https://www.insitro.com
insitro的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- South San Francisco，California
- 类型
- 私人持股
- 创立
- 2018
- 领域
- biotech、machine learning、data science、drug development、science和life science
地点
-
主要
获取路线
259 E Grand Ave
US，California，South San Francisco，94080
insitro员工
动态
-
Join insitro CEO and founder Daphne Koller at WIRED Health in London next Tuesday, March 18 as she takes the keynote stage! ?? Daphne will be sharing an inside look at how insitro’s approach to #drugdiscovery is building a pipeline of high-conviction targets through #machinelearning, #AI and data at scale. To register, visit the link below and get 25% off tickets using the code SPEAKER25. https://lnkd.in/e6tf6KAy
-
-
Thank you Lloyd Minor and The Minor Consult for having insitro CEO and founder Daphne Koller on the podcast! Take a listen to their full conversation at the link below. ??
Carl and Elizabeth Naumann Dean, Stanford University School of Medicine
I was delighted to welcome Daphne Koller, founder and CEO of the biotech company insitro, to The Minor Consult podcast, for a conversation about AI and its potential to transform drug discovery. We discussed how machine learning algorithms can accelerate the process for designing new therapies, and we explored the challenges and opportunities of founding a startup in Silicon Valley. Thank you for joining me, Daphne! Listen to our whole discussion at the link below: https://lnkd.in/gHVjSGdD
-
Thank you?Forbes for including insitro as a Best Startup Employer for the fourth year running!??? Our insitrocytes are working every?day to deliver better medicines for patients using the power of #machinelearning and data at scale, so we can make?medicines ... differently. https://lnkd.in/eyUWiPR7
Introducing America's Best Startup Employers: Smart startups know that keeping employees happy is good for both the workers and the business. And though it’s not easy to assess which companies consistently maintain employee engagement and satisfaction, Forbes has made it easier by researching and ranking America’s Best Startup Employers 2025. SEE LIST: https://trib.al/9O2hj6i
-
-
insitro CFO/CBO Mary Rozenman will be on site at Biocom California’s Global Life Science Partnering & Investor Conference on Tuesday, February 25 for “AI & Drug Discovery: It’s Not As Easy As It Looks,” moderated by John Carroll, Endpoints News Editor. She joins peers in both biotech and pharma on the panel including Thomas Miller, Justin Scheer, and Marc Tessier-Lavigne to discuss ongoing advances in #AI-driven #drugdiscovery. Register at the link?https://lnkd.in/gAiGskMh
-
-
insitro CSO Philip Tagari joins the BioScience Forum Wednesday, February 19 to outline how insitro is building a "pipeline through platform," taking a pragmatic approach to technology with one goal: to find better medicines for challenging conditions in #neuroscience and liver diseases. Grab a spot on the waitlist for a chance to join for an evening of networking, dinner and a presentation on insitro’s unique approach. https://lnkd.in/e-nJfHRf
-
-
Thanks to the San Francisco Business Times for including insitro CEO and founder Daphne Koller in their Newsmakers 100 list, recognizing the great partnerships and developments we announced with both Eli Lilly and Company and Bristol Myers Squibb in 2024. ?? Read more about Daphne and the other impressive recipients at the link here ?? https://lnkd.in/eBMsEgPi
-
-
At insitro we are working to identify and prosecute targets of high conviction using the power of #AI and data at scale, including developing our own statistical genetic methods. Our latest paper proposes a modified approach to the growing practice of performing GWAS on ratio traits, which are used to improve statistical power, but risk conflating signals in associations. Instead, we propose and validate a simple method to account for this common pitfall. Taking obesity as an example, we show how using the denominator as a covariate better captures the genetics of obesity-related traits than signals from the standard ratio model (BMI). We believe this approach can help enhance the rigor and level of confidence for GWAS findings, so insitro and the wider research community can keep developing new biological insights. For more, read our thread on Bluesky and view the paper in the link below. https://lnkd.in/ejz6TEGS
-
Our insitrocytes are the heartbeat of our shared vision. Together, as builders, scientists, engineers, we solve complex challenges every day, laser-focused on delivering better medicines for patients. Hear directly from some of our colleagues about how we work. Visit https://lnkd.in/dMtcA9Uz.
Culture at insitro